Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 April 2021
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Artificial Intelligence technologies for assessing skin lesions selected for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointmentsStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: TBC